Lung Cancer
Conditions
Brief summary
The feasibility and impact of respiratory rehabilitation (RR) in patients with advanced or metastatic (EGF-R WT or mutated) non-small cell lung cancer treated with oral targeted therapy including Inhibitors of EGF-R tyrosine kinases (TKI) and ALK inhibitors. These patients will benefit, at the beginning of the chemotherapy whatever the treatment line, of a respiratory rehabilitation. The respiratory rehabilitation takes place at the patient's home with the HAD's cooperation 3 hours per week, divided into 2 or 3 sessions. There is associated educational, nutritional and psychological support for a total duration of 8 weeks.
Interventions
It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
Sponsors
University Hospital, Lille
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Patients with advanced or metastatic non-small cell lung cancer treated with oral targeted therapy (tyrosine kinase (TKI) inhibitors of EGF-R and ALK inhibitors), regardless of the treatment line.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with advanced or metastatic lung cancer * In the course of treatment by oral chemotherapy of oral targeted therapy (tyrosine kinase inhibitor) in 1st, 2nd, 3rd line or more at the time of their inclusion * Diagnosis of CP retained after multidisciplinary discussion of patient records
Exclusion criteria
* Any residual toxicity of a previous antineoplastic treatment, grade\> 2. * Cardio-respiratory contraindications to exercise re-training: * Angina unstable * Recent infarct * Tight aortic stenosis * Unsteady heart failure * Pericarditis, endocarditis, myocarditis * Evolutionary thromboembolic disease * Ventricular aneurysm * Intra ventricular thrombus * Uncontrolled rhythm disorders * Instability of the respiratory state defined by uncompensated respiratory acidosis * Carcinological contraindications: * Bone metastases at risk of fracture and / or algae despite optimal analgesic treatment, symptomatic central nervous system metastases * Presence of anemia (Hb \<8g / dl or \<10g / dl if patient with previous cardiac history), thrombocytopenia (\<100,000 platelets / mm3) * Chimio toxicity (neurological, cardiac) according to the investigator's assessment * Neuromuscular contraindications: * Neuromuscular and / or osteo-articular disease making it impossible to re-train * Severe cognitive impairment * Patient under tutorship or curatorship
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients completing the full Respiratory Rehabilitation (8 weeks) at home | At 8 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EORTC QLQ C-30 standardized version 3.0 | Baseline and 8 weeks | Measure the quality of life |
| Functional capacity | Baseline and 8 weeks | Exercise capacity with the six minutes walk test |
| Respiratory capacity | Baseline and 8 weeks | measured by the spirometry |
| Functional Assessment of Cancer Therapy Lung standardized | Baseline and 8 weeks | measure the quality of life |
| Body Mass Index | Baseline and 8 weeks | — |
| Overall and progression-free survival | at 6 months | — |
| Nutritional Risk Screening score | Baseline and 8 weeks | Nutritional state assessment by albumine and pre albumine dosage |
Countries
France
Outcome results
None listed